

# Multiple independent variants in 6q21-22 associated with susceptibility to celiac disease in the Dutch, Finnish and Hungarian populations

Elisabet Einarsdottir, Marianna R Bevova, A Zhernakova, Alienke Monsuur, Lotta L. E. Koskinen, Ruben Vant Slot, Chris J.J. Mulder, M. Luisa Mearin, Ilma Korponay-Szabo, Katri Kaukinen, et al.

# ▶ To cite this version:

Elisabet Einarsdottir, Marianna R Bevova, A Zhernakova, Alienke Monsuur, Lotta L. E. Koskinen, et al.. Multiple independent variants in 6q21-22 associated with susceptibility to celiac disease in the Dutch, Finnish and Hungarian populations. European Journal of Human Genetics, 2011, 10.1038/ejhg.2011.2. hal-00614742

# HAL Id: hal-00614742 https://hal.science/hal-00614742

Submitted on 16 Aug 2011  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

### 1 Title

- 2 Multiple independent variants in 6q21-22 associated with susceptibility to celiac
- 3 disease in the Dutch, Finnish and Hungarian populations
- 4 Running title: Celiac disease susceptibility at 6q21-22 in European populations

### 5 Authors:

- 6 Elisabet Einarsdottir 1\*, Marianna R. Bevova 2,3\*, Alexandra Zhernakova 2, 4,
- 7 Alienke Monsuur 2, Lotta L.E. Koskinen 1, Ruben van't Slot 2, Chris Mulder 5, M.
- 8 Luisa Mearin 6, Ilma R. Korponay-Szabo 7, Katri Kaukinen 8, Kalle Kurppa 9 Juha
- 9 Kere 10, Markku Mäki 9, Cisca Wijmenga 11, Päivi Saavalainen 1

10

11 \* Equal author contribution

## 12 Affiliations

- 13 1. Department of Medical Genetics and Research Program for Molecular Medicine,
- 14 Biomedicum Helsinki, P.O. Box 63, FIN-00014 University of Helsinki, Finland
- 15 2. Department of Medical Genetics, University Medical Centre Utrecht, The
- 16 Netherlands.
- 17 3. Department of Clinical Genetics, VU University Medical Center, Amsterdam, The
- 18 Netherlands
- 19 4. Department of Rheumatology, Leiden University Medical Center, The Netherlands
- 20 5. Department of Gastroenterology, VU University Medical Center, Amsterdam, The
- 21 Netherlands
- 22 6. Department of Paediatric Gastroenterology, Leiden University Medical Centre,
- 23 Leiden, The Netherlands.

| 24 | 7. Heim Pal Child | ren's Hospital, H-108 | 9 Budapest and Univ | versity of Debrecen, H- |
|----|-------------------|-----------------------|---------------------|-------------------------|
|----|-------------------|-----------------------|---------------------|-------------------------|

- 25 4032 Debrecen, Hungary
- 26 8. Department of Gastroenterology and Alimentary Tract Surgery, Tampere
- 27 University Hospital and Medical School, University of Tampere, Tampere, Finland
- 28 9. Paediatric Research Centre, University of Tampere Medical School and Tampere
- 29 University Hospital, FIN-33014 University of Tampere, Finland
- 30 10. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, and
- 31 Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden
- 32 11. Department of Genetics, University Medical Center Groningen, and University of
- 33 Groningen, P.O. Box 30001, 9700 RB Groningen, the Netherlands
- 34
- 35

## 36 **Corresponding author**

- 37
- 38 Elisabet Einarsdottir, Ph.D.
- 39 Department of Medical Genetics and
- 40 Research Program for Molecular Medicine
- 41 Biomedicum Helsinki
- 42 P.O. Box 63
- 43 FIN-00014 University of Helsinki
- 44 Finland
- 45 Tel +358-9-19125107
- 46 Fax +358-9-19125624
- 47 E-mail elisabet.einarsdottir@helsinki.fi

### 50 **Abstract**

51 Celiac disease is an inflammatory enteropathy caused by intolerance to gluten. 52 Previous linkage studies in the Dutch, Finnish and Hungarian populations have 53 revealed a locus on chromosome 6q21-22 conferring susceptibility to celiac disease. 54 This locus has previously been implicated in susceptibility to other autoimmune 55 diseases such as Crohn's disease and type 1 diabetes. We performed finemapping on 56 446 independent individuals with celiac disease and 641 controls of Dutch origin, 57 testing 872 tagging SNPs in a 22 Mb region of chromosome 6. The twelve most 58 promising SNPs were followed up in 2071 individuals from 284 Finnish and 357 59 Hungarian celiac disease families to identify risk variants in this region. 60 Multiple markers in the region were significantly associated with celiac disease in the 61 Dutch material. Two SNPs, rs9391227 and rs4946111, were significantly associated 62 with celiac disease in the Finnish population. The association to rs9391227 represents 63 the strongest association signal found in the Finnish (p=0.0032, OR 0.66) as well as 64 the combined Dutch, Finnish and Hungarian populations (p=3.6\*10-5, OR 0.76). 65 Rs9391227 is situated downstream of the HECT domain and ankyrin repeat 66 containing, E3 ubiquitin protein ligase 1 (HACE1) gene and is contained within a 67 region of strong linkage disequilibrium enclosing HACE1. Two additional, 68 independent, susceptibility variants in the 6q21-22 region were also found in a meta-69 analysis of the three populations. The 6q21-22 region was confirmed as a celiac 70 disease susceptibility locus and harbours multiple independent associations, some of 71 which may implicate ubiquitin-pathways in celiac disease susceptibility.

48

49

72

- 73 Keywords:
- 74 Celiac, linkage, association, genome-wide, 6q21-22

75

### 76 Introduction

77 Celiac disease is a chronic autoimmune disorder of the small intestine with 78 autoimmune features. It is triggered in genetically susceptible individuals by dietary 79 exposure to gluten, a protein present in wheat, barley and rye. Ingestion of gluten by 80 celiac disease patients leads to flattening of the duodenal mucosa, a gradual process 81 classified according to Marsh  $^{(1)}$ . With a prevalence above 1%  $^{(2)}$ , celiac disease is the 82 most common food intolerance in general western populations. Long regarded as a 83 gastrointestinal disorder of childhood, the disease is now considered to be a chronic 84 systemic autoimmune disease and is more and more often diagnosed in adults <sup>(3)</sup>. 85 Celiac disease is a multifactorial disorder and both environmental factors, such as 86 gluten, and a multigenic predisposition are needed to explain the aetiology of the 87 disease. Concordance rates for celiac disease have been shown to be higher in 88 monozygous twins (86%) than in dizygous twins (20%), indicating a strong genetic component in the development of celiac disease <sup>(4)</sup>. Celiac disease aggregates in 89 90 families with an approximate 10% recurrence risk for siblings of celiac disease 91 patients. There is, however, no clear Mendelian inheritance of the disease in families, 92 suggesting that the genetic predisposition is derived from the presence and interaction 93 of more than one susceptibility gene.

94

95 Over 90% of celiac disease patients express the HLA-DQ2 heterodimer, encoded by
96 DQA1\*0501 and DQB1\*02. A causal role for HLA-DQ2 has been demonstrated as
97 this molecule can present the gluten-derived peptides to T-cells <sup>(5)</sup>. A further 5% of
98 celiac disease patients carry HLA-DQ8. Although HLA-DQ2 or DQ8 seem to be
99 necessary for celiac disease development, they are not sufficient, as HLA-DQ2 or

DQ8 alone can only explain some 40% of the genetic variation underlying celiac
disease. This implies that other, non-*HLA* genes, are also important determinants of
disease aetiology.

103

A recent whole-genome association scan identified a number of genetic variants involved in celiac disease susceptibility <sup>(6)</sup>. However, all the known risk variants explain not more than 50% of the genetic variance of celiac disease, indicating that novel genes and novel risk variants remain to be identified. This was supported by the results of the second whole-genome association study in celiac disease <sup>(7)</sup>. This study confirmed a number of the previously identified risk variants, as well as identifying numerous novel variants.

111

112 A study in the Dutch population obtained evidence for linkage of celiac disease to the 6q21-22 region, approximately 70 cM downstream of the *HLA* region <sup>(8)</sup>. The region 113 114 of interest spans approximately 102 to 122 Mb and is clearly distinct from the HLA 115 region as well as from the previously identified TNFAIP3 and TAGAP celiac susceptibility genes <sup>(9, 10)</sup>. An independent study by Einarsdottir *et al.* (unpublished) of 116 117 susceptibility genes for celiac disease in Finnish and Hungarian families also showed 118 linkage to 6q16-22, to a region overlapping with the linkage found in the Dutch 119 population. Taken together, these results indicate the possibility of a genetic factor 120 within the chromosome 6q21-22 region that is involved in susceptibility to celiac 121 disease in multiple populations. We therefore performed a fine-mapping scan in 122 Dutch unrelated individuals with celiac disease in order to identify the possible 123 candidate gene. This study was further followed up in family datasets from the 124 Finnish and Hungarian populations.

## 126 Material and methods

#### 127 **Patients and controls**

#### 128 **Dutch cohort:**

129 DNA from whole blood was available from a cohort of Dutch individuals with celiac

130 disease. All the affected individuals were diagnosed in accordance with the revised

131 ESPGHAN criteria <sup>(11)</sup>. The control cohort comprising random blood bank donors and

has been described previously <sup>(6)</sup>. All 446 Dutch cases and 641 controls were from the

133 Netherlands and of European descent, and at least three of their four grandparents

134 were also born in The Netherlands. The sample set has been described previously <sup>(12)</sup>.

135 This study was approved by the Medical Ethical Committee of the University Medical

136 Centre Utrecht.

137

#### 138 **Finnish and Hungarian cohorts:**

139 The Finnish families and cases were collected at the University of Tampere and have been described previously<sup>(13)</sup>. The collection of the Hungarian samples has also been 140 described previously (14). A total of 1001 individuals from 284 Finnish families (19 141 142 unknown phenotype, 359 healthy, 623 affected) and 1070 individuals from 357 143 Hungarian families (7 unknown phenotype, 471 healthy, 592 affected) were included 144 for genotyping. All sample collections were approved by the ethical committees of the 145 Tampere and Helsinki University Hospitals, Finnish National Public Health Institute, 146 Heim Pal Children's Hospital, Budapest, and the University of Debrecen. All

participants were informed about the study according to the study protocol and gavetheir written informed consent.

149

### 150 Marker selection and genotyping

151 For a comprehensive follow-up screen in an independent Dutch dataset, we took the 152 lod-1 region (95% confidence interval; ranging from rs9390679 (101,261,700 bp) to 153 rs11154152 (123,694,693 bp) (National Center for Biotechnology Information NCBI34/hg16) of the previously identified linkage peak on chromosome 6<sup>(15)</sup>. SNPs 154 155 for fine-mapping were selected by downloading all the SNPs typed in the CEPH 156 (Centre d'Etude du Polymorphisme Humain) population (Utah residents with ancestry 157 from northern and western Europe) that were located in the genomic sequence of the 158 region of interest from the HapMap database (November 2004, Phase I, 159 http://www.hapmap.org/). The program Tagger (available at 160 http://www.broad.mit.edu/mpg/tagger/) was subsequently used to select tag SNPs to 161 cover the region. We used  $r^2 \ge 0.7$  to perform pairwise tagging. Additionally we set up 162 a minor allele frequency (MAF) cut off  $\geq$ 5% and took Illumina quality design scores 163 into account for preferential picking of SNPs that are more likely to work on the 164 Illumina platform. The obtained tag SNPs were genotyped using the GoldenGate 165 assay on an Illumina BeadStation 500 GX (Illumina Inc., San Diego, USA). After 166 genotyping all tag SNPs from the initial scan in the Dutch cohort were examined for 167 their resulting quality; all those that were not polymorphic, had a low signal or had 168 clusters that were too wide were excluded (data not shown). In addition, tag SNP that 169 deviated from Hardy-Weinberg equilibrium (HWE) in the controls (p < 0.001) were 170 excluded from further analysis, yielding a final set of 872 tag SNPs obtained for 171 genotype analysis.

| 173 | For the replication in Finnish and Hungarian cohorts, we chose the 18 markers            |
|-----|--|
| 174 | showing the highest allelic association in the Dutch cohort (p< $0.01$ ). 14 of the SNPs |
| 175 | showed the highest association in the unadjusted model and 4 additional SNP were         |
| 176 | chosen from the top markers in a sex adjusted model ( $p<0.01$ ). As the differences in  |
| 177 | the analysis were not very large we have not proceeded further with the sex adjusted     |
| 178 | model (data not shown). The markers were genotyped by MALDI-TOF analysis on              |
| 179 | the Massarray Analyzer platform (Sequenom, San Diego, USA). Genotyping was               |
| 180 | performed at the MAF core facility in Karolinska Institute, Stockholm, Sweden.           |
| 181 | Genotyping results and sample information were collected in a BC GENE LIMS               |
| 182 | database (Biocomputing Platforms, Espoo, Finland). As five markers in the                |
| 183 | replication study failed (assay design failed or call rate < 90%, data not shown),       |
| 184 | genotype information for twelve SNP markers was available for analysis.                  |
| 185 | Deviations from Mendelian inheritance in the family materials were determined with       |
| 186 | PEDCHECK 1.1 $^{(16)}$ . Mendelian errors were detected in 0.21% of genotypes in the     |
| 187 | Finnish samples, and in 0.17% of the genotypes in the Hungarian samples. All             |
| 188 | genotypes of a marker were discarded in a family if inheritance errors were detected.    |
| 189 |  |
| 190 | To ensure that the annotation of the rs9391227 SNP on both the Illumina and              |
| 191 | Sequenom platforms was performed on the same strand, we performed an additional          |
| 192 | genotyping of rs9391227 on the Taqman platform using 12 controls from Finland            |
| 193 | (previously genotyped by Sequenom) and 54 Dutch celiac disease cases and controls        |
| 194 | (previously genotyped by Illumina). All the samples showed 100% concordance of           |
| 195 | the genotypes obtained on different platforms (data not shown).                          |

#### 196 Association analysis

For the initial association analysis in the Dutch sample set, we performed a single
SNP association test using the Haploview program <sup>(17)</sup>.

Unphased (version 3.0)<sup>(18)</sup> was used to look for association in families by calculating 199 200 allele counts in affected offspring and comparing these with counts from 201 untransmitted alleles from parents and unaffected offspring. All affected individuals 202 in a family were used in the association analysis. As each affected individual within a 203 family is not independent, this constitutes in effect, a test of linkage in the presence of 204 possible association. 205 Unphased was also used to perform a meta-analysis of the Finnish, Hungarian and 206 Dutch sample sets. Population differences were assessed by a global Wald test. All 207 reported p-values two-tailed and uncorrected unless noted. Only single-marker 208 association analysis was performed as the genetic markers in the follow-up study were 209 too distant from each other. Permutation testing (1000 permutations) was used to

estimate empirical p-values, allowing for multiple testing corrections over all tests

211 performed in a run. PLINK (version 1.06) was used to perform quantitative trait

analysis in order to explore if the associated markers were possible eQTLs for the

213 genes within a 200 kb window around them.

210

### 214 **Power analysis of follow-up study**

The Genetic Power Calculator program (<u>http://pngu.mgh.harvard.edu/~purcell/gpc/</u>)
 (<sup>19)</sup> was used to estimate the power of the Finnish and Hungarian family-based

association analysis to replicate the association in the Dutch case-control samples.

218 Parameters for power estimation in the Finnish and Hungarian follow-up materials

were estimated from the initial Dutch results and marker rs1998166 as it showed the
highest association in the discovery phase. We estimated the power to replicate the
association to rs1998166 (protective allele frequency 0.123, odds-ratio 0.616, and
celiac disease prevalence 0.01) in the 284 Finnish families to be 64%, and in the 357
Hungarian families to be 74%. When combining the Finish and Hungarian samples
we had an estimated power of 93%.

### 225 **Results**

#### 226 Dutch association

In this study, we performed finemapping of the 6q linkage region by genotyping 872 SNP markers in 446 cases and 641 controls. The association of each SNP to celiac disease is shown in figure 1 and supplementary table 1. From 872 SNPs, 18 showed association at p<0.01 and were included for replication in CD families from Finland and Hungary.

232

233 Because population sub-structure is a possible cause for false positive results, this 234 issue has been investigated previously for all the Dutch cases and a majority of the 235 controls as a part of another study (Carolien de Kovel, unpublished data). No 236 significant population structure was detected using the STRUCTURE software 237 (http://pritch.bsd.uchicago.edu/structure.html). The likelihood of increasing numbers 238 of subpopulations decreased continuously, indicating that it is more likely that the 239 individuals were drawn from a single population than from two or more. Also, the 240 assignment of the individuals to the different sub-populations, when the software was 241 forced to create more than one, was never significantly different between cases and 242 controls (Caroline de Kovel, unpublished data). In view of these results, it is unlikely that the results of the association analysis in the Dutch dataset were due to populationsub-structure.

#### **Follow-up association in Finnish and Hungarian families**

246 Table 1 shows the markers studied in the follow-up association study. The empirical 247 5% quantile of the best p-values for the Finnish dataset was 0.0029, 0.0033 for the 248 Hungarian dataset, and 0.0027 for the combined Finnish, Hungarian and Dutch 249 dataset (the markers with p-values lower than these are denoted by \* in table 1). Three 250 SNPs showed consistent replication in either the Finnish or Hungarian families, to the 251 same allele as observed in the Dutch population. Association analysis revealed that 252 the T-allele of rs9391227 was associated with protection from celiac disease in 253 Finnish families (p 0.0032, OR 0.66), as well as allele T of rs4946111 (p 0.006479, 254 OR 0.66). Allele T of rs9391227 also showed a trend of association with celiac 255 disease in Hungarian families. No other markers were associated with celiac disease 256 in the Hungarian family material.

257

258 Association to SNP rs9391227 located downstream of HACE1 and within a region of 259 strong LD surrounding the HACE1 gene was confirmed in a meta-analysis of the 260 Finnish and Hungarian family datasets and the Dutch case-control dataset (p 261 3.625\*10-5, protective allele T OR 0.76). Even if we correct for multiple testing of 262 the 872 SNPs originally tested for, this signal remains significant (Pc = 0.032). This 263 represents the strongest association in the combined materials, and it is stronger than 264 in the Dutch case-control dataset alone. Two additional markers showed a strong 265 association in the meta-analysis, these were rs1998166 (p 0.0002, OR 1.56), located in 266 the RWDD1 gene and rs4946578 (p 0.0018, OR 1.25), located upstream from the 267 GJA1 gene. The association signal of these two markers to celiac disease appears to

be contributed to by all three populations, as the meta-p value is lower than that in the
Dutch dataset only, and the allele frequency differences in patients and controls show
the same trend in each of the populations.

271

272 Tests of heterogeneity between the datasets yielded significant differences (p < 0.05)

between populations in the markers rs2216084, rs1146229, rs9487060 and rs4946111.

274 It is expected that there will be significant differences between allele frequencies even

in well sampled datasets from different populations. The markers rs2216084,

rs1146229, and rs9487060, while showing some association in the Dutch dataset,

show very little indication of association in the Finnish and Hungarian datasets. This

is not likely to be only due to different allele frequencies as the Dutch and Hungarian

279 datasets show similar frequencies in these markers. Rather, it may be due to different

280 haplotype backgrounds in the different populations. Marker rs4946111 shows some

association in the Finnish dataset, but less in the Dutch populations. Furthermore, the

282 effect is even reversed in the Hungarian population. This marker may thus constitute a

283 locus on a highly heterogeneous haplotype background between the studied

284 populations. The association in the Finnish samples may be due to an otherwise rare

285 mutation enriched in the Finnish population through genetic drift.

286

An analysis (data not shown) in 40 Finnish control samples (Dukes et al. 2010,

288 unpublished) identified no evidence of eQTLs regarding markers

289 rs9391227 and HACE1, rs1998166 and RWDD1, rs4946578 and GJA1, nor of

rs9391227 and PREP expression. PREP is not in LD with rs9391227 (data not

shown), further arguing against genetic factors within PREP itself explaining the

association with rs9391227. Variation at rs9391227 may still, however, be in LD with
and have effects on *PREP* regulatory regions outside of the gene itself.

### 295 **DISCUSSION**

In this study we followed up previous findings of linkage to 6q21-22 in celiac disease
by performing a fine-mapping study in the Dutch population, and a replication study
in the Finnish and Hungarian populations.

### 299 HACE1 & rs9391227

- 300 In the combined analysis we identified association of rs9391227 to celiac disease in
- 301 three populations using both case-control and family datasets. Rs9391227 is an
- 302 intergenic SNP downstream of and within a region of strong LD surrounding the
- 303 HACE1 gene (suppl fig 1). HACE1 (HECT domain and ankyrin repeat containing, E3
- 304 ubiquitin protein ligase 1) is an ubiquitination-protein ligase. As celiac disease is
- 305 believed to be due, at least to some extent, to dysregulation of the immune system and
- 306 antigen presentation, the importance of ubiquitination in celiac disease is plausible.
- 307 Whether rs9391227 is involved in this mechanism is unknown. .

#### 308 **Rs1998166 and rs4946578**

- 309 The marker that is second most strongly independently associated with celiac disease
- 310 in the meta-analysis is rs1998166. This marker is within an intron of the RWD
- domain containing 1 (*RWDD1*) gene. Little is known about this gene, but the RWD
- 312 domain is found in RING finger and WD repeat containing proteins and in the
- 313 DEXDc-like helicase subfamily, related to the ubiquitin-conjugating enzymes
- 314 domain.

316 The third, independent, association found in the meta-analysis was to rs4946578. This 317 marker is approx. 124kb away from, but contained within an LD block that contains 318 the Gap junction protein, alpha 1, 43kDa (GJA1, CX43) gene. This gene is a member 319 of the connexin gene family and encodes for a component of gap junctions. Connexin-320 43 is the major protein of gap junctions in the heart, and gap junctions are thought to 321 have a crucial role in the synchronized contraction of the heart and in embryonic 322 development. Mutations in this gene have also been found in deafness <sup>(20)</sup> and in palmoplantar keratoderma<sup>(21)</sup>. 323

324

#### 325 **PREP**

326 The genetic region we studied on 6q also harbours the gene encoding prolyl

327 endopeptidase (PREP), an enzyme able to cleave proline-rich gluten peptides. An

altered PREP activity in the intestinal mucosa could be responsible for the inefficient

329 breakdown of gluten peptides, thus contributing to the onset of celiac disease. *PREP* 

has previously been identified as a potential celiac disease candidate; however, a

331 previous study indicated no association of this gene with celiac disease in the Dutch

332 population <sup>(22)</sup>. Although this gene is located within the region studied in the current

333 Dutch, Finnish and Hungarian samples, no indication was found that this gene could334 explain the linkage and/or association to 6q.

335

### 336 Multiple associations and implications

Linkage to 6q21-22 was found in two independent whole-genome linkage studies, andfollowing up the results, we found association to multiple independent SNPs in the

| 339 | Dutch, Finnish, and Hungarian populations. This replication in several independent                          |
|-----|---|
| 340 | datasets makes the association signals in the region credible and likely to be true                         |
| 341 | celiac disease risk factors. We did not find one single gene with a major effect on                         |
| 342 | celiac disease susceptibility, suggesting that there may be several susceptibility genes                    |
| 343 | at this locus, each with small effects. The previously conducted GWAS on celiac                             |
| 344 | disease failed to identify strong associations to celiac disease in the studied region on                   |
| 345 | chromosome 6. There are 8 SNPs among the top 1000 signals from the GWAS of                                  |
| 346 | Dubois <i>et al.</i> <sup>(7)</sup> , which are located in this region, These association signals, however, |
| 347 | are in distinct LD blocks (D' $\leq$ 0.2) from the two most highly associated markers in                    |
| 348 | our study (data not shown). Furthermore, the current study is estimated to adequately                       |
| 349 | tag the eight GWAS signals (data not shown). Of the markers in our study, only three                        |
| 350 | (rs1146229, rs2282854, and rs4946578) were also included in the Dubois GWAS                                 |
| 351 | study, allowing for a direct comparison of association signals. These three markers                         |
| 352 | were significantly associated with celiac disease neither in the meta-analysis within                       |
| 353 | the Dubois GWAS study nor in the Finnish or Dutch populations (data not shown),                             |
| 354 | these markers were not part of the follow-up study. In addition to this, the arrays used                    |
| 355 | in the GWAS do not contain perfect proxies for the most highly associated markers in                        |
| 356 | our study (data not shown), arguing that the association we see in the current study                        |
| 357 | may have been missed in the GWAS. We thus conclude that our results likely indicate                         |
| 358 | true association that is independent of the GWAS signals, and that it is unlikely that                      |
| 359 | we are missing major associations at this locus due to insufficient marker coverage.                        |
| 360 |   |
| 361 | The current study cannot fully explain the underlying cause of the multiple                                 |
| 362 | independent association signals in the region. The multiple association signals show                        |
| 363 | the complexity of disease susceptibility in the region, but the results are consistent in                   |

the different study populations and the observed risk effect of the associated variants
is relatively high. This argues that each of the identified variants (or nearby untyped
variants in LD with the associated variants) is a true, novel, susceptibility factor for
celiac disease.

368

### 369 ACKNOWLEDGEMENTS

370 All the study subjects are thanked for participating in the study. We thank the Dutch 371 Celiac Disease Foundation for participating in this study, H. van Someren and F. 372 Mulder for clinical database management, and Ruben van't Slot at UMC Utrecht for 373 technical assistance. We thank Wieke HM Verbeek for help in sample collection and 374 Jackie Senior for critical reading of the manuscript. We thank Hanne Ahola and Anne 375 Heimonen for excellent technical assistance and Erzsébet Szathmári, Judit B.Kovács, 376 Margit Lörincz and Anikó Nagy for their work with the Hungarian families. We thank 377 Carolien de Kovel at UMC Utrecht for providing unpublished data on the population 378 structure of the Dutch cohort. We acknowledge funding from the Coeliac Disease 379 Consortium (an innovative cluster approved by the Netherlands Genomics Initiative 380 and partly funded by the Dutch Government, grant BSIK03009 to CW); the 381 Netherlands Organization for Scientific Research (VICI grant 918.66.620 to CW) and 382 the Dutch Digestive Disease Foundation. This work has been funded by the EU 383 Commission through a Marie Curie Excellence Grant (FP6 contract MEXT-CT-2005-384 025270 to PS), by the Academy of Finland, the Hungarian Scientific Research Fund 385 (contract OTKA 61868), the University of Helsinki Funds, Biocentrum Helsinki, the 386 Competitive Research Funding of the Tampere University Hospital, the Foundation of 387 Pediatric Research and the Sigrid Juselius Foundation.

# 390 CONFLICT OF INTEREST

- 391 The authors declare no conflict of interest.
- 392

## 393 **REFERENCES**

- 394 1. Marsh M. N. Gluten, major histocompatibility complex, and the small intestine. A
- molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac
   sprue'). *Gastroenterology* 1992;102:330-354.
- 2. Lohi S., Mustalahti K., Kaukinen K., *et al.* Increasing prevalence of coeliac disease
- 398 over time. *Aliment.Pharmacol.Ther.* 2007;**26:**1217-1225.
- 399 3. Ravikumara M., Tuthill D. P. and Jenkins H. R. The changing clinical presentation
  400 of coeliac disease. *Arch.Dis. Child.* 2006;**91:**969-971.
- 401 4. Greco L., Romino R., Coto I., *et al.* The first large population based twin study of coeliac disease. *Gut* 2002;**50:**624-628.
- 403 5. Molberg O., Mcadam S. N., Korner R., *et al.* Tissue transglutaminase selectively
- 404 modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease.
  405 *Nat.Med.* 1998;4:713-717.
- 406 6. van Heel D. A., Franke L., Hunt K. A., *et al.* A genome-wide association study for
- 407 celiac disease identifies risk variants in the region harboring IL2 and IL21. *Nat.Genet.*408 2007;**39:**827-829.
- 409 7. Dubois P. C., Trynka G., Franke L., et al. Multiple common variants for celiac
- 410 disease influencing immune gene expression. *Nat.Genet.* 2010;**42:**295-302.
- 411 8. Van Belzen M. J., Meijer J. W., Sandkuijl L. A., et al. A major non-HLA locus in
- 412 celiac disease maps to chromosome 19. *Gastroenterology* 2003;**125**:1032-1041.
- 413 9. Hunt K. A., Zhernakova A., Turner G., et al. Newly identified genetic risk variants
- 414 for celiac disease related to the immune response. *Nat.Genet.* 2008;**40**:395-402.
- 415 10. Trynka G., Zhernakova A., Romanos J., et al. Coeliac disease associated risk
- 416 variants in TNFAIP3 and REL implicate altered NF-{kappa}B signalling. Gut 2009;
- 417 11. Anonymous Revised criteria for diagnosis of coeliac disease. Report of Working
- 418 Group of European Society of Paediatric Gastroenterology and Nutrition.
- 419 Arch.Dis.Child. 1990;65:909-911.
- 420 12. Monsuur A. J., de Bakker P. I., Alizadeh B. Z., et al. Myosin IXB variant
- 421 increases the risk of celiac disease and points toward a primary intestinal barrier
- 422 defect. Nat. Genet. 2005;37:1341-1344.
- 423 13. Koskinen L. L., Einarsdottir E., Dukes E., et al. Association study of the IL18RAP
- 424 locus in three European populations with coeliac disease. *Hum.Mol.Genet*.
- 425 2009;**18:**1148-1155.
- 426 14. Koskinen L. L., Korponay-Szabo I. R., Viiri K., et al. Myosin IXB gene region
- 427 and gluten intolerance: linkage to coeliac disease and a putative dermatitis
- 428 herpetiformis association. J.Med.Genet. 2008;45:222-227.

388

389

- 429 15. van Belzen M. J., Vrolijk M. M., Meijer J. W., et al. A genomewide screen in a
- 430 four-generation Dutch family with celiac disease: evidence for linkage to
- 431 chromosomes 6 and 9. Am.J.Gastroenterol. 2004;99:466-471.
- 432 16. O'Connell J. R. and Weeks D. E. PedCheck: a program for identification of
- 433 genotype incompatibilities in linkage analysis. Am.J.Hum.Genet. 1998;63:259-266.
- 434 17. Barrett J. C., Fry B., Maller J. and Daly M. J. Haploview: analysis and
- 435 visualization of LD and haplotype maps. *Bioinformatics* 2005;**21:**263-265.
- 436 18. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes.
- 437 *Genet.Epidemiol.* 2003;25:115-121.
- 438 19. Purcell S., Cherny S. S. and Sham P. C. Genetic Power Calculator: design of
- 439 linkage and association genetic mapping studies of complex traits. *Bioinformatics*
- 440 2003;**19:**149-150.
- 441 20. Paznekas W. A., Karczeski B., Vermeer S., et al. GJA1 mutations, variants, and
- 442 connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype.
- 443 *Hum.Mutat.* 2009;**30:**724-733.
- 444 21. van Steensel M. A., Spruijt L., van der Burgt I., *et al.* A 2-bp deletion in the GJA1
- 445 gene is associated with oculo-dento-digital dysplasia with palmoplantar keratoderma.
- 446 *Am.J.Med.Genet.A.* 2005;**132A:**171-174.
- 447 22. Diosdado B., Stepniak D. T., Monsuur A. J., et al. No genetic association of the
- 448 human prolyl endopeptidase gene in the Dutch celiac disease population.
- 449 Am.J.Physiol.Gastrointest.Liver Physiol. 2005;289:G495-500.
- 450
- 451

# 452 TITLES AND LEGENDS TO FIGURES

453

454 Figure 1. Association of SNPs in the chromosome 6 region to celiac disease in the

455 Dutch cohort. SNP positions are based on NCBI Build 35 and are given in Mb.

456 Diamonds represent individual SNPs.

457

458 Table 1. SNP markers in the study and their association to celiac disease in Dutch

459 cases and controls (A) as well as Finnish (B) and Hungarian (C) families, and a meta-

460 analysis of all three populations (D). Case frequencies, in the family materials, refer to

the allele frequencies of the affected offspring ("cases") and the control frequencies

462 refer to both unaffected offspring ("healthy") and the untransmitted alleles in parents.

463 P-values lower than 0.01 are considered significant (marked in bold) and odds ratios

464 (OR) and 95% OR confidence intervals for significant markers are given.

- 465 Emp permutation p-values are based on 10000 permutations.
- 466

467 Supplementary table 1. Allelic and genotypic association of 860 SNP markers to

468 celiac disease in Dutch cases and controls. The 12 markers chosen for follow-up

469 analysis are shown in bold and underlined. Genotype counts (11,12,22), Hardy-

470 Weinberg (HW) p-values and allelic and genotypic p-values are shown.





### Table 1 - SNP markers and association in follow-up study

|           |               |         | A DUTCH (446 cases, 641 controls) |         |             | B FINNISH (623 cases, 359 healthy) |                 |         | C HUNGARIAN (592 cases, 471 healthy) |                 |         | D FINNISH, HUNGARIAN, DUTCH (1661 cases, 1471 controls) |                 |             |                  |
|-----------|---------------|---------|-----------------------------------|---------|-------------|------------------------------------|-----------------|---------|--------------------------------------|-----------------|---------|---|-----------------|-------------|------------------|
| Markers   | Position (bp) | Alleles | case,contr freq                   | p value | emp p-value | OR (95% CI)                        | case,contr freq | p value | OR (95% CI)                          | case,contr freq | p value | OR (95% CI)   | case,contr freq | p value     | OR (95% CI)      |
| rs1648957 | 104613397     | СТ      | 0.498, 0.433                      | 0.003   | 0.005       | 1.30 (1.09-1.55)                   | 0.449, 0.481    | 0.351   |                                      | 0.545, 0.519    | 0.440   |   | 0.498, 0.460    | 0.085       |                  |
| rs9391227 | 105265327     | AT      | 0.497, 0.559                      | 0.005   | 0.003       | 0.78 (0.66-0.93)                   | 0.541, 0.651    | 0,003*  | 0.66 (0.49-0.88)                     | 0.495, 0.555    | 0.054   |   | 0.507, 0.577    | 3.07*10-5 * | 0.76 (0.66-0.86) |
| rs2895615 | 106292441     | CG      | 0.690, 0.642                      | 0.020   | 0.018       | 1.25 (1.03-1.50)                   | 0.668, 0.641    | 0.398   |                                      | 0.679, 0.678    | 0.871   |   | 0.683, 0.649    | 0.061       |                  |
| rs2216084 | 107660005     | СТ      | 0.646, 0.688                      | 0.045   | 0.058       | 0.83 (0.69-0.99)                   | 0.809, 0.757    | 0.048   | 1.41 (0.99-1.99)                     | 0.706, 0.676    | 0.603   |   | 0.700, 0.699    | 0.836       |                  |
| rs1146229 | 109205720     | СТ      | 0.085, 0.052                      | 0.002   | 0.003       | 1.72 (1.22-2.43)                   | 0.111, 0.118    | 0.673   |                                      | 0.070, 0.095    | 0.082   |   | 0.087, 0.075    | 0.259       |                  |
| rs9487060 | 109741149     | CG      | 0.079, 0.048                      | 0.003   | 0.002       | 1.73 (1.21-2.47)                   | 0.067, 0.072    | 0.724   |                                      | 0.060, 0.062    | 0.763   |   | 0.072, 0.054    | 0.032       | 1.36 (1.03-1.79) |
| rs2503770 | 110373108     | AT      | 0.233, 0.274                      | 0.031   | 0.028       | 0.80 (0.66-0.98)                   | 0.324, 0.313    | 0.884   |                                      | 0.237, 0.217    | 0.376   |   | 0.255, 0.269    | 0.536       |                  |
| rs571060  | 112403213     | СТ      | 0.970, 0.987                      | 0.007   | 0.010       | 0.44 (0.24-0.81)                   | 0.992, 0.993    | 1.000   |                                      | 0.982, 0.978    | 0.841   |   | 0.978, 0.986    | 0.085       |                  |
| rs2282854 | 112638353     | СТ      | 0.933, 0.962                      | 0.003   | 0.003       | 0.55 (0.37-0.82)                   | 0.968, 0.965    | 0.796   |                                      | 0.948, 0.938    | 0.452   |   | 0.946, 0.958    | 0.170       |                  |
| rs4946111 | 116091112     | GT      | 0.445, 0.502                      | 0.011   | 0.008       | 0.80 (0.67-0.95)                   | 0.385, 0.482    | 0.007   | 0.66 (0.49-0.90)                     | 0.434, 0.390    | 0.280   |   | 0.429, 0.474    | 0.020       | 0.86 (0.76-0.98) |
| rs1998166 | 117020110     | СТ      | 0.921, 0.877                      | 0.001   | 0.003       | 1.62 (1.20-2.19)                   | 0.940, 0.917    | 0.105   |                                      | 0.956, 0.928    | 0.087   |   | 0.934, 0.896    | 2.17*10-4 * | 1.56 (1.22-1.98) |
| rs4946578 | 121936760     | AG      | 0.584, 0.534                      | 0.023   | 0.023       | 1.23 (1.03-1.46)                   | 0.732, 0.695    | 0.323   |                                      | 0.564, 0.536    | 0.421   |   | 0.606, 0.558    | 0.002       | 1.25 (1.09-1.44) |